keyword
MENU ▼
Read by QxMD icon Read
search

Remission depression

keyword
https://www.readbyqxmd.com/read/28928174/exercise-for-patients-with-major-depression-a-systematic-review-with-meta-analysis-and-trial-sequential-analysis
#1
Jesper Krogh, Carsten Hjorthøj, Helene Speyer, Christian Gluud, Merete Nordentoft
OBJECTIVES: To assess the benefits and harms of exercise in patients with depression. DESIGN: Systematic review DATA SOURCES: Bibliographical databases were searched until 20 June 2017. ELIGIBILITY CRITERIA AND OUTCOMES: Eligible trials were randomised clinical trials assessing the effect of exercise in participants diagnosed with depression. Primary outcomes were depression severity, lack of remission and serious adverse events (eg, suicide) assessed at the end of the intervention...
September 18, 2017: BMJ Open
https://www.readbyqxmd.com/read/28926793/early-symptomatic-improvement-affects-treatment-outcome-in-a-study-of-major-depressive-disorder
#2
Steven D Targum
Early symptomatic improvement immediately following randomization can affect signal detection in clinical trials. The impact of early improvement of the Montgomery-Asberg depression rating scale (MADRS) on eventual treatment outcome was examined in a 6-week, double-blind, placebo-controlled trial of a putative antidepressant (CX157) versus placebo in depressed subjects with major depressive disorder (MDD) who had had an inadequate response to ongoing antidepressant treatment (NCT00739908). MADRS score changes within one week after randomization directly affected treatment outcome at the study endpoint (week 6)...
September 8, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28925030/drug-repurposing-may-generate-novel-approaches-to-treating-depression
#3
REVIEW
Mohamed Elsaed Ebada
OBJECTIVES: The breakthrough advancements in scientific medical research have greatly improved our understanding of the pathogenesis of depression, encouraging drug discoverers to take a shorter path than ever through drug repurposing to generate new antidepressant medications. In addition to reduced noradrenergic and serotonergic neurotransmission in the brain, other coincidence features such as glutamate neurotoxicity, inflammation and/or cerebrovascular insufficiency are implicated in the pathogenesis of major depressive disorder and late-life depression...
September 18, 2017: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/28919117/global-regional-and-national-incidence-prevalence-and-years-lived-with-disability-for-328-diseases-and-injuries-for-195-countries-1990-2016-a-systematic-analysis-for-the-global-burden-of-disease-study-2016
#4
(no author information available yet)
BACKGROUND: As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016. METHODS: We estimated prevalence and incidence for 328 diseases and injuries and 2982 sequelae, their non-fatal consequences...
September 16, 2017: Lancet
https://www.readbyqxmd.com/read/28918241/stigma-experienced-by-patients-with-severe-mental-disorders-a-nationwide-multicentric-study-from-india
#5
Sandeep Grover, Ajit Avasthi, Aakanksha Singh, Amitava Dan, Rajarshi Neogi, Darpan Kaur, Bhavesh Lakdawala, Abhijit R Rozatkar, Naresh Nebhinani, Suravi Patra, Priya Sivashankar, Alka A Subramanyam, Adarsh Tripathi, Ab Majid Gania, Gurvinder Pal Singh, Prakash Behere
This study aimed to evaluate the stigma and its correlates among patients with severe mental disorders. Patients with diagnosis of schizophrenia (N = 707), bipolar disorder (N = 344) and recurrent depressive disorder (N = 352) currently in clinical remission from 14 participating centres were assessed on Internalized Stigma of Mental Illness Scale (ISMIS). Patients with diagnosis of schizophrenia experienced higher level of alienation, sterotype endorsement, discrimination experience and total stigma when compared to patients with bipolar disorder and recurrent depressive disorder...
August 17, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28911960/characterization-of-the-adrenocorticotrophic-hormone-induced-mouse-model-of-resistance-to-antidepressant-drug-treatment
#6
Bettadapura N Srikumar, Mahesh Paschapur, Narasimharaju Kalidindi, Bharath Adepu, Manish L Das, Muppana V Sreedhara, Vijaya K Kuchibhotla, Rick L Pieschl, Yu-Wen Li, Durga Shiva Prasad Ega, Justin Louis, Senthilkumar Murugesan, Pattipati S Naidu, Manjunath Ramarao, Linda J Bristow, Reeba K Vikramadithyan
Approximately 30-60% of patients treated with existing antidepressants fail to achieve remission of depressive symptoms leading to Treatment Resistant Depression (TRD). There is an urgent need to develop novel medications, which is highly limited by the non-availability of relevant animal models with good predictive validity. ACTH administration has been shown to result in the resistance to acute and chronic effects of imipramine. However, the pharmacology of the model and the mechanisms contributing to the resistance are not completely understood...
September 11, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28911851/cortisol-awakening-response-in-patients-with-bipolar-disorder-during-acute-episodes-and-partial-remission-a-pilot-study
#7
Ming-Chyi Huang, Shan-Chi Chuang, Mei-Chih Meg Tseng, Yi-Ling Chien, Shih-Cheng Liao, Hsi-Chung Chen, Po-Hsiu Kuo
This exploratory study examined the cortisol awakening response (CAR) in patients with bipolar disorder (BPD) at acute phases and partial remission of manic or depressive episodes. Saliva samples of twenty-seven BPD inpatients and 25 healthy controls were collected to determine the CAR patterns, and 12 patients were sampled again at partial remission. BPD patients exhibited a non-enhanced CAR pattern. Lower cortisol expression and a blunted CAR distinguished bipolar-depressive patients from the controls. The intra-individual follow-up for both patient groups revealed a non-significant improvement in CAR patterns, indicating a trend of a normalized CAR after partial remission for BPD patients...
September 1, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28905640/neurobiological-mechanisms-of-exercise-and-psychotherapy-in-depression-the-speed-study-rationale-design-and-methodological-issues
#8
Stephan Heinzel, Michael A Rapp, Thomas Fydrich, Andreas Ströhle, Christina Terán, Gunnar Kallies, Melanie Schwefel, Andreas Heissel
BACKGROUND/AIMS: Even though cognitive behavioral therapy has become a relatively effective treatment for major depressive disorder and cognitive behavioral therapy-related changes of dysfunctional neural activations were shown in recent studies, remission rates still remain at an insufficient level. Therefore, the implementation of effective augmentation strategies is needed. In recent meta-analyses, exercise therapy (especially endurance exercise) was reported to be an effective intervention in major depressive disorder...
September 1, 2017: Clinical Trials: Journal of the Society for Clinical Trials
https://www.readbyqxmd.com/read/28903122/impact-of-ixekizumab-treatment-on-depressive-symptoms-and-systemic-inflammation-in-patients-with-moderate-to-severe-psoriasis-an-integrated-analysis-of-three-phase-3-clinical-studies
#9
Christopher E M Griffiths, Maurizio Fava, Andrew H Miller, James Russell, Susan G Ball, Wen Xu, Nayan Acharya, Mark Hyman Rapaport
BACKGROUND: Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, was evaluated in patients with moderate-to-severe plaque psoriasis (psoriasis) and depressive symptoms that were at least moderately severe. METHODS: Data were integrated from 3 randomized, double-blind, controlled phase 3 trials. At baseline and week 12, depressive symptoms and inflammation were assessed by the 16-item Quick Inventory of Depressive Symptomology - Self-Report (QIDS-SR16) and by a high-sensitivity assay of serum C-reactive protein (hsCRP), respectively...
September 14, 2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28898283/sustained-effectiveness-and-cost-effectiveness-of-the-healthy-activity-programme-a-brief-psychological-treatment-for-depression-delivered-by-lay-counsellors-in-primary-care-12-month-follow-up-of-a-randomised-controlled-trial
#10
Benedict Weobong, Helen A Weiss, David McDaid, Daisy R Singla, Steven D Hollon, Abhijit Nadkarni, A-La Park, Bhargav Bhat, Basavraj Katti, Arpita Anand, Sona Dimidjian, Ricardo Araya, Michael King, Lakshmi Vijayakumar, G Terence Wilson, Richard Velleman, Betty R Kirkwood, Christopher G Fairburn, Vikram Patel
BACKGROUND: The Healthy Activity Programme (HAP), a brief behavioural intervention delivered by lay counsellors, enhanced remission over 3 months among primary care attendees with depression in peri-urban and rural settings in India. We evaluated the sustainability of the effects after treatment termination, the cost-effectiveness of HAP over 12 months, and the effects of the hypothesized mediator of activation on clinical outcomes. METHODS AND FINDINGS: Primary care attendees aged 18-65 years screened with moderately severe to severe depression on the Patient Health Questionnaire 9 (PHQ-9) were randomised to either HAP plus enhanced usual care (EUC) (n = 247) or EUC alone (n = 248), of whom 95% completed assessments at 3 months, and 91% at 12 months...
September 2017: PLoS Medicine
https://www.readbyqxmd.com/read/28891153/a-randomized-trial-of-off-site-collaborative-care-for-depression-in-chronic-hepatitis-c-virus
#11
Fasiha Kanwal, Jeffrey M Pyne, Shahriar Tavakoli-Tabasi, Susan Nicholson, Brian Dieckgraefe, Erma Storay, Matthew Bidwell Goetz, Jennifer R Kramer, Donna Smith, Shubhada Sansgiry, Aylin Tansel, Allen L Gifford, Steven M Asch
OBJECTIVE: To test the effectiveness of a collaborative depression care model in improving depression and hepatitis C virus (HCV) care. DATA SOURCES/STUDY SETTING: Hepatitis C virus clinic patients who screened positive for depression at four Veterans Affairs Hospitals. STUDY DESIGN: We compared off-site depression collaborative care (delivered by depression care manager, pharmacist, and psychiatrist) with usual care in a randomized trial...
September 11, 2017: Health Services Research
https://www.readbyqxmd.com/read/28890910/six-month-outcomes-for-collaborative-care-management-of-depression-among-smoking-and-nonsmoking-patients
#12
Daniel R Witt, Gregory M Garrison, Cesar A Gonzalez, Terrence J Witt, Kurt B Angstman
BACKGROUND: Collaborative care management (CCM) is an evidence-based model that contributes to better outcomes for depression treatment in the primary care setting. Tobacco use increases overall economic costs, morbidity, and mortality and has been shown to impact behavioral health outcomes. Our study aims to observe clinical outcomes for depression treatment for patients with comorbid tobacco use and depression within the CCM model. METHODS: A retrospective chart review study of 2826 adult patients with depression enrolled in CCM was performed to determine the association between regular tobacco use and depression outcomes...
January 2017: Health Services Research and Managerial Epidemiology
https://www.readbyqxmd.com/read/28890584/interactive-q-learning-for-quantiles
#13
Kristin A Linn, Eric B Laber, Leonard A Stefanski
A dynamic treatment regime is a sequence of decision rules, each of which recommends treatment based on features of patient medical history such as past treatments and outcomes. Existing methods for estimating optimal dynamic treatment regimes from data optimize the mean of a response variable. However, the mean may not always be the most appropriate summary of performance. We derive estimators of decision rules for optimizing probabilities and quantiles computed with respect to the response distribution for two-stage, binary treatment settings...
2017: Journal of the American Statistical Association
https://www.readbyqxmd.com/read/28884421/assessing-responsiveness-over-time-of-the-promis-%C3%A2-pediatric-symptom-and-function-measures-in-cancer-nephrotic-syndrome-and-sickle-cell-disease
#14
Bryce B Reeve, Lloyd J Edwards, Byron C Jaeger, Pamela S Hinds, Carlton Dampier, Debbie S Gipson, David T Selewski, Jonathan P Troost, David Thissen, Vaughn Barry, Heather E Gross, Darren A DeWalt
PURPOSE: Previous studies provided evidence for the validity of the PROMIS Pediatric measures in cross-sectional studies. This study evaluated the ability of the PROMIS Pediatric measures to detect change over time in children and adolescents with cancer, nephrotic syndrome (NS), or sickle cell disease (SCD). METHODS: Participants (8-17 years) completed measures of fatigue, pain interference, anger, anxiety, depressive symptoms, mobility, upper extremity, and peer relationships at three or four time points (T1-T4)...
September 7, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28884353/a-prospective-longitudinal-investigation-of-the-dis-continuity-of-mental-health-difficulties-between-mid-to-late-childhood-and-the-predictive-role-of-familial-factors
#15
Cliodhna O'Connor, Udo Reulbach, Blanaid Gavin, Fiona McNicholas
Understanding individual variation in the continuity of youth mental health difficulties is critical for identifying the factors that promote recovery or chronicity. This study establishes the proportion of children showing psychopathology at 9 years, whose pathology had either remitted or persisted at 13. It describes the socio-demographic and clinical profiles of these groups, and examines the factors in 9-year-olds' familial environments that predict longitudinal remission vs. persistence of psychopathology...
September 7, 2017: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/28882405/efficacy-of-quetiapine-xr-vs-placebo-as-concomitant-treatment-to-mood-stabilizers-in-the-control-of-subthreshold-symptoms-of-bipolar-disorder-results-from-a-pilot-randomized-controlled-trial
#16
Marina Garriga, Eva Solé, Ana González-Pinto, Gabriel Selva-Vera, Belén Arranz, Benedikt L Amann, Jerónimo Saiz-Ruiz, Josefina Pérez-Blanco, Eduard Vieta
Patients with bipolar disorder (BD) do not always achieve full remission between episodes. Subthreshold symptoms (depressive, manic or mixed) represent a major cause of relapse and disability in these patients. Immediate release (IR) and extended release (XR) formulations of quetiapine are both indicated for short and long-term treatment of BD. The aim of this study was to evaluate the efficacy of quetiapine XR vs placebo in subthreshold symptomatology when added to previous mood stabilizer treatment. A pilot phase IIIB, multicentre, prospective, placebo controlled, randomized, double blinded study of 12 weeks follow-up was performed (NCT01197846)...
September 4, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28876379/clinical-outcomes-of-psychotherapy-dropouts-does-dropping-out-of-psychotherapy-necessarily-mean-failure
#17
Rodrigo T Lopes, Miguel M Gonçalves, Dana Sinai, Paulo P Machado
Objective: A large proportion of psychotherapy patients remain untreated, mostly because they drop out. This study compares the short- and long-term outcomes of patients who dropped out of psychotherapy to those of therapy completers. Methods: The sample included 63 patients (23 dropouts and 40 completers) from a controlled clinical trial, which compared narrative therapy vs. cognitive-behavioral therapy for major depressive disorder. Patients were assessed at the eighth session, post-treatment, and at 31-month follow-up...
August 30, 2017: Revista Brasileira de Psiquiatria
https://www.readbyqxmd.com/read/28875975/-autobiographical-memory-in-depressive-disorders
#18
REVIEW
Paulina Żuchowicz, Justyna Jasionowska, Piotr Gałecki, Monika Talarowska
Contemporary research studies regarding autobiographical memory (AM) indicate that its deficits have a significant impact on the development of mental disorders. We find particularly many reports regarding the comorbidity of AM deficits and depressive disorders. The characteristic feature of AM in the people suffering from depressive disorders is the presence of overgeneral autobiographical memory (OGM), i.e. the reminiscences which contain a summary of many emotion-laden situations, yet without significant detail...
August 21, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28868159/the-effects-of-residential-dual-diagnosis-treatment-on-alcohol-abuse
#19
Stephen J Schoenthaler, Kenneth Blum, Lyle Fried, Marlene Oscar-Berman, John Giordano, Edward J Modestino, Rajendra Badgaiyan
This multi-center study of dual diagnosis (DD) programs involved 804 residential patients with co-occurring alcohol and mental health disorders. The Addiction Severity Index was administered at admission and at one, six, and 12 months after discharge. Repeated measures analysis showed the intoxication rate per month stabilized between months six and 12 with 68% still in remission and an 88% mean reduction from baseline (F = 519, p < .005). A comparison between patients with and without weekly relapse produced significant differences in hospitalization (odds ratio 11...
July 2017: Journal of Systems and Integrative Neuroscience
https://www.readbyqxmd.com/read/28867363/methoxetamine-produces-rapid-and-sustained-antidepressant-effects-probably-via-glutamatergic-and-serotonergic-mechanisms
#20
Chrislean Jun Botanas, June Bryan de la Peña, Raly James Custodio, Irene Joy Dela Peña, Mikyung Kim, Taeseon Woo, Hee Jin Kim, Hye In Kim, Min Chang Cho, Yong Sup Lee, Jae Hoon Cheong
Depression afflicts around 16% of the world's population, making it one of the leading causes of disease burden worldwide. Despite a number of antidepressants available today, the delayed onset time and low remission rate of these treatments are still a major challenge. The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has shown to produce rapid and sustained antidepressant effects and has paved the way for a new generation of glutamate-based antidepressants. Methoxetamine (MXE) is a ketamine analogue that acts as an NMDA receptor antagonist and a serotonin reuptake inhibitor...
September 1, 2017: Neuropharmacology
keyword
keyword
120775
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"